This is the authors' abstract. We don't add key points for this paper.
We evaluated 70 HIV-infected pregnant women with CD4⁺ cell count >350 cells per cubic millimeter who received zidovudine, lamivudine, and nevirapine from week 25 of gestation until 6 months after delivery and a 3-week tail of zidovudine and lamivudine at the moment of drug discontinuation. Forty days after the interruption of all drugs resistance mutations were present in 5 of 70 (7.1%) women. Two of them had the same mutation archived in baseline HIV DNA. The other 3 women had, at least once, detectable viral load and presence of mutations during treatment. Overall, the risk of developing resistance mutations in compliant women was low.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Palombi et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: